MissionIR Articles

For well over a hundred years, industrialized nations have continued to export a wide range of manufactured goods and associated technologies to developing countries throughout the world. More than altruism, it was viewed as an…

Today, Cardium Therapeutics announced the EU approval of uniQure’s Glybera® (alipogene tiparvovec). This first gene therapy approval by a major health regulatory authority represents a significant milestone and validation for the gene therapy industry. Glybera®…

When the FDA recently announced that it is considering a faster approval process for developers of drugs for serious diseases, it was important news for companies like Cardium Therapeutics, a San Diego-based health sciences and…

The recent acquisition by Cardium Therapeutics, a health sciences and regenerative medicine company, of To Go Brands, a private California-based nutraceutical company, is in line with Cardium’s strategy of accelerating the growth and development of…

A recent article in Genetic Engineering & Biotechnology News, the world’s number one biotech publisher, carried a good report on Cardium Therapeutics and Generx, a Cardium product candidate. Generx is a DNA-based angiogenic growth factor…

Cardium Therapeutics, known for the acquisition and strategic development of tissue repair and therapy technologies, also has a dynamic in-house healthy lifestyle product platform called MedPodium. Designed as a portfolio of premium, science-based nutraceuticals, metabolics,…

Cardium Therapeutics this morning announced that its MedPodium® business has acquired the assets, business, and product portfolio of privately held To Go Brands® to support the expansion of its health sciences nutraceutical brand platform. Following…

Cardium Therapeutics’ Generx product candidate is a good example of the company’s strategy of acquiring and developing new and innovative bio-medical product opportunities addressing unmet medical needs on a worldwide basis. Generx (alferminogene tadenovec, Ad5FGF-4)…

Today before the opening bell, Cardium Therapeutics announced that Chairman & CEO Christopher J. Reinhard will be presenting at the BioX Noble Financial Life Sciences Exposition being held at the University of Connecticut, Stamford Campus…

Today before the opening bell, Cardium Therapeutics announced the formation of the new Excellagen Medical Advisory Board. Comprised of leading practitioners, clinicians, and researchers with diversified expertise in the field of advanced wound care, the…

Cardium Therapeutics, a San Diego based health sciences and regenerative medicine company, is focused on the acquisition and development of new and innovative bio-medical product opportunities and businesses offering the potential of addressing significant unmet…

Cardium Therapeutics is a health sciences and regenerative medicine company whose focus is on the acquisition and development of innovative products with the potential to address significant unmet medical needs. These innovative products should have…

Cardium Therapeutics today announced that Chairman & CEO Christopher J. Reinhard will be giving a presentation at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012, at 3:15 p.m. Eastern Time.…

Cardium Therapeutics, a San Diego based medical technology company, working with Michigan based Essen Bioscience, Inc., has come up with an important new bio-assay potency test for use with Generx, the company’s advanced clinical stage…

In a July interview conducted by CEOCFO Magazine, Cardium Therapeutics’ co-founder, Executive Chairman, and CEO, Christopher J. Reinhard, had an opportunity to explain the many developments that have occurred with the company since its founding…

Today before the opening bell, Cardium Therapeutics issued a press release detailing its financial results for the second quarter ended June 30, 2012, as well as reported on other recent developments including: (1) agreement with…

My husband has type 2 diabetes, and since his diagnosis a year-and-a-half ago I’ve had to incorporate the word “carbohydrate” into my vocabulary and use it. Often. Diabetes is a real balancing act. If my…

Cardium Therapeutics offers a dramatic new approach in the treatment of heart disease with the company’s product candidate Generx® (alferminogene tadenovec, Ad5FGF-4), a DNA-based angiogenic growth factor being developed for the treatment of patients with…

Cardium Therapeutics just reported that its professional-use Excellagen® (formulated collagen gel 2.6%) wound care product has been named one of the top ten podiatry innovations this year by the publication Podiatry Today. The company also…

It wasn’t long ago that gene therapy, an idea that has been around since at least the early 1970s, was being derided as more hype than hope. Gene therapy basically involves identifying that part of…